Impact of 1st and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy:: Preliminary results of FIRST, a prospective community-based study

被引：0
|
作者：
Ozer, H
Mirtsching, B
Rader, M
Ding, B
Dansey, R
机构：
[1] Univ Oklahoma, Ctr Canc, Oklahoma City, OK USA
[2] Ctr Oncol Res & Treatment, Dallas, TX USA
[3] Hematol Oncol Rockland, New City, NY USA
[4] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：758S / 758S
页数：1
相关论文
共 27 条
  • [1] Final results of a large, community-based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in patients receiving myelosuppressive chemotherapy.
    Ozer, H.
    Mirtsching, B.
    Rader, M.
    Ding, B.
    Truscinski, D.
    Dreiling, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 485S - 485S
  • [2] First and subsequent cycle pegfilgrastim results in low rates of neutropenic events in patients receiving myelosuppressive chemotherapy.
    Rader, ME
    Breyer, W
    Luedke, S
    Truscinski, D
    Ding, B
    Dansey, R
    Ozer, H
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S215 - S216
  • [3] Patients with non-Hodgkin's lymphoma receiving myelosuppressive chemotherapy with first and subsequent cycle pegfilgrastim support experience low rates of neutropenic complications: Preliminary results of FIRST, a prospective community-based study.
    Ozer, H
    Noga, SJ
    Morrison, VA
    Ding, BY
    Dansey, R
    BLOOD, 2005, 106 (11) : 256B - 256B
  • [4] Final results of a large, community based, prospective study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events.
    Rader, M.
    Ding, B.
    Dreiling, L.
    Ozer, H.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S283 - S283
  • [5] Low incidence of neutropenic events in patients with lymphoma receiving first-cycle pegfilgrastim with chemodierapy: Results from a prospective community-based study
    Noga, Stephen J.
    Choksi, Janak K.
    Ding, Beiying
    Dreiling, Lyndah
    Ozer, Howard
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (06): : 413 - 420
  • [6] Final results of a large, community based study evaluating the impact of first and subsequent cycle pegfilgrastim on neutropenic events in NHL and HD patients.
    Noga, Stephen J.
    Choksi, Janak
    Ding, Beiying
    Dreiling, Lyndah
    Ozer, Howard
    BLOOD, 2006, 108 (11) : 341A - 341A
  • [7] First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: Results from a prospective nationwide study.
    Crawford, J
    Wolff, DA
    Culakova, E
    Poniewierski, MS
    Selby, C
    Dale, DC
    Lyman, GH
    BLOOD, 2004, 104 (11) : 607A - 608A
  • [8] A PROSPECTIVE-STUDY OF 1000 1ST STROKE PATIENTS ADMITTED TO A COMMUNITY-BASED PRIMARY CARE HOSPITAL - THE LAUSANNE STROKE REGISTRY, LAUSANNE, SWITZERLAND
    BOGOUSSLAVSKY, J
    VANMELLE, G
    REGLI, F
    CEREBRAL VASCULAR DISEASE 7, 1989, 858 : 161 - 163
  • [9] Pegfilgrastim nearly abrogates occurrence of neutropenic events early in the course of chemotherapy: results of a phase 3, randomized, double-blind, placebo-controlled study of patients with breast cancer receiving docetaxel.
    Vogel, C
    Rader, M
    Tyulandin, S
    Wiens, B
    Neumann, T
    Carroll, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S198 - S199
  • [10] Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study
    Lutrino, Stefania Eufemia
    Bergamo, Francesca
    Schirripa, Marta
    Rosati, Gerardo
    Avallone, Antonio
    Giampieri, Riccardo
    Cordio, Stefano
    Berretta, Massimiliano
    Llimpe, Fabiola Rojas
    Pisa, Federica Edith
    Lonardi, Sara
    Loupakis, Fotios
    Fasola, Gianpiero
    Aprile, Giuseppe
    ANTICANCER RESEARCH, 2015, 35 (04) : 2391 - 2399
123